These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 2139173)

  • 41. The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study.
    Kahn JO; Allan JD; Hodges TL; Kaplan LD; Arri CJ; Fitch HF; Izu AE; Mordenti J; Sherwin JE; Groopman JE
    Ann Intern Med; 1990 Feb; 112(4):254-61. PubMed ID: 2297204
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Analysis of potential risk factors associated with the development of pancreatitis in phase I patients with AIDS or AIDS-related complex receiving didanosine.
    Grasela TH; Walawander CA; Beltangady M; Knupp CA; Martin RR; Dunkle LM; Barbhaiya RH; Pittman KA; Dolin R; Valentine FT
    J Infect Dis; 1994 Jun; 169(6):1250-5. PubMed ID: 8195601
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I study of continuous-infusion soluble CD4 as a single agent and in combination with oral dideoxyinosine therapy in children with symptomatic human immunodeficiency virus infection.
    Husson RN; Chung Y; Mordenti J; Butler KM; Chen S; Duliege AM; Brouwers P; Jarosinski P; Mueller BU; Ammann A
    J Pediatr; 1992 Oct; 121(4):627-33. PubMed ID: 1357124
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quantitative analysis of HIV-1 proviral DNA in peripheral blood mononuclear cells from patients with AIDS or ARC: decrease of proviral DNA content following treatment with 2',3'-dideoxyinosine (ddI).
    Aoki S; Yarchoan R; Thomas RV; Pluda JM; Marczyk K; Broder S; Mitsuya H
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1331-9. PubMed ID: 2127682
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. A phase I trial.
    Drusano GL; Yuen GJ; Lambert JS; Seidlin M; Dolin R; Valentine FT
    Ann Intern Med; 1992 Apr; 116(7):562-6. PubMed ID: 1347442
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection.
    Hartman NR; Yarchoan R; Pluda JM; Thomas RV; Marczyk KS; Broder S; Johns DG
    Clin Pharmacol Ther; 1990 May; 47(5):647-54. PubMed ID: 2111751
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of therapy with didanosine on hematologic parameters in patients with advanced human immunodeficiency virus disease.
    Schacter LP; Rozencweig M; Beltangady M; Allan JD; Canetta R; Cooley TP; Dolin R; Kelley S; Lambert J; Liebman HA
    Blood; 1992 Dec; 80(12):2969-76. PubMed ID: 1467512
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome.
    Barry M; Howe JL; Ormesher S; Back DJ; Breckenridge AM; Bergin C; Mulcahy F; Beeching N; Nye F
    Br J Clin Pharmacol; 1994 May; 37(5):421-6. PubMed ID: 8054247
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase 1 study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complex.
    Hodges TL; Kahn JO; Kaplan LD; Groopman JE; Volberding PA; Amman AJ; Arri CJ; Bouvier LM; Mordenti J; Izu AE
    Antimicrob Agents Chemother; 1991 Dec; 35(12):2580-6. PubMed ID: 1810192
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Population pharmacokinetic analysis of didanosine (2',3'-dideoxyinosine) plasma concentrations obtained in phase I clinical trials in patients with AIDS or AIDS-related complex.
    Pai SM; Shukla UA; Grasela TH; Knupp CA; Dolin R; Valentine FT; McLaren C; Liebman HA; Martin RR; Pittman KA
    J Clin Pharmacol; 1992 Mar; 32(3):242-7. PubMed ID: 1564128
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.
    Abrams DI; Kuno S; Wong R; Jeffords K; Nash M; Molaghan JB; Gorter R; Ueno R
    Ann Intern Med; 1989 Feb; 110(3):183-8. PubMed ID: 2463780
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pancreatitis and pancreatic dysfunction in patients taking dideoxyinosine.
    Seidlin M; Lambert JS; Dolin R; Valentine FT
    AIDS; 1992 Aug; 6(8):831-5. PubMed ID: 1418780
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial.
    Browne MJ; Mayer KH; Chafee SB; Dudley MN; Posner MR; Steinberg SM; Graham KK; Geletko SM; Zinner SH; Denman SL
    J Infect Dis; 1993 Jan; 167(1):21-9. PubMed ID: 8093363
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients.
    Li RC; Narang PK; Sahai J; Cameron W; Bianchine JR
    Antimicrob Agents Chemother; 1997 Jul; 41(7):1566-70. PubMed ID: 9210686
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acute pancreatitis as a common complication of 2',3'-dideoxyinosine therapy in the acquired immunodeficiency syndrome.
    Maxson CJ; Greenfield SM; Turner JL
    Am J Gastroenterol; 1992 Jun; 87(6):708-13. PubMed ID: 1590305
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Substitution of didanosine sachets by chewable tablets: a pharmacokinetic study in patients with AIDS.
    Burger D; Meenhorst P; Mulder J; Henrichs J; Frissen J; Kroon F; ten Napel C; Koks K; Bult A; Beijnen J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Oct; 10(2):163-8. PubMed ID: 7552480
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term follow-up of didanosine administered orally twice daily to patients with advanced human immunodeficiency virus infection and hematologic intolerance of zidovudine.
    Allan JD; Connolly KJ; Fitch H; Jackson-Pope L; McLaren C; Canetta R; Groopman JE
    Clin Infect Dis; 1993 Feb; 16 Suppl 1():S46-51. PubMed ID: 8425019
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children.
    Balis FM; Pizzo PA; Butler KM; Hawkins ME; Brouwers P; Husson RN; Jacobsen F; Blaney SM; Gress J; Jarosinski P
    J Infect Dis; 1992 Jan; 165(1):99-104. PubMed ID: 1727902
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection.
    Faulds D; Brogden RN
    Drugs; 1992 Jul; 44(1):94-116. PubMed ID: 1379914
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and tolerance of dideoxycytidine as a single agent. Results of early-phase studies in patients with acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex. Study Group of the AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
    Merigan TC; Skowron G
    Am J Med; 1990 May; 88(5B):11S-15S. PubMed ID: 2159703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.